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Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) is the principal curative therapy for disorders of the haematopoietic system but it is still associated with substantial morbidity and mortality (Copelan (2006) , Gratwohl et al. (2007) ) with a survival rate of 40-60% (Balavarca et al. (2015) ). Five main clinical factors influencing outcome after HSCT have been established by the European Group for Blood and Marrow Transplantation (EBMT).
These EBMT-factors (patient age, stage of the disease, time interval from diagnosis to transplant, histocompatibility and donor and patient gender combination) have been successfully utilised in a clinical risk score (EBMT risk score) (Gratwohl (2012) ) for all patients undergoing HSCT for a haematological disorder (Gratwohl et al. (2009)) (Supplementary Table 1) .
Recently several groups, including ourselves, have used both small cohorts (Dickinson (2008) , Mullally & Ritz (2007) ) and genome-wide association studies (GWAS) (Chien et al. (2012)) to demonstrate that polymorphisms within non-HLA genes are predictive of HSCT outcome.
The effect of gene polymorphisms may be influenced by year of transplant; transplant protocols have been modified over the last ten years due to increased use of reduced intensity conditioning, increased use of peripheral blood stem cells rather than bone marrow and increased age of the patient at time of transplant (Feinstein et al. (2001) ) thus altering the biology of HSCT.
In this study we investigated the role of non-HLA polymorphisms in a cohort of acute leukaemia patients with HLA matched sibling and matched unrelated donors. The influence of change in transplant protocols over time was also assessed. The results from the non-HLA genetic analysis were used to derive a novel (and validated) statistical model for overall survival which integrated non-HLA genetics into the EBMT risk score. Gene polymorphisms were also investigated for their association with non-relapse mortality, relapse and acute and chronic graft versus host disease.
All patients and donors gave informed consent in accordance with EBMT guidelines and the Declaration of Helsinki. The protocol was approved by the Local Research Ethics Committee at the co-ordinating centre (Newcastle upon Tyne).
Materials and Methods

Patients
Data were available from a total of 458 adult acute leukaemia patients (330 acute myeloid leukaemia, 123 acute lymphoblastic leukaemia, 3 acute biphenotypic leukaemia and 2 acute undifferentiated leukaemia) and were collected prospectively from 8 European transplant centres. Transplants were conducted between 1983 and 2005. All clinical data were collected from the EBMT database ProMIse. In this cohort, 58% of patients had died and 30% of patients had relapsed. HLA typing was determined by standard technologies using serology or molecular typing. Of the 458 patients, 29% received reduced intensity conditioning and 34% were T cell depleted. All patients received standard comparative supportive care across centres.
The median follow up time was 77 months. Causes of death were stated as relapse (46%), acute respiratory distress syndrome (ARDS)/infection (21%), graft versus host disease (GvHD) (18%) and 'other' (15%). Clinical relapse was defined as hematologic, cytogenetic or molecular relapse (Branford (2007) ). Patient and donor characteristics are presented in Table   1 .
Genotyping for cytokine polymorphisms
Archived frozen peripheral blood mononuclear cells were used for the preparation of DNA.
Genotyping was carried out by Kbioscience (http://www.kbioscience.co.uk) who used fluorescence-based competitive PCR technology (KASPar) and designed the assays for the SNPs based on the DNA sequence (50 bases) either side of the SNP. Genotypes were available for 32 non-HLA candidate polymorphisms from 20 genes (Supplementary Table 2 ).
These SNPs were chosen according to findings on smaller patient cohorts by our coordinating centre in Newcastle (ESR1 ), IFNG (Pravica et al. (1999) ), IL1RN (Hurme & Santtila (1998) ), IL4 (Walley & Cookson (1996) ), IL6 (Cavet et al. (2001) , Yee et al. (2009) ), IL10 (Morse et al. (1999) ), IL13 (Graves et al. (2000) ), TNF (Imboden et al. (2006) ), TNFRSF1B (Stark et al. (2003) ) and VDR (Middleton et al. (2002) )) and according to findings by other HSCT groups (MAL (Rocha et al. (2007) ), MDR1 (Kim et al. (2006)) and NOD2 (Holler et al. (2004) ). Candidate SNPs were also selected according to previous disease association studies in autoimmune (CD14 (Klein et al. (2002) ), GCR (Derijk et al. (2001) , Stevens et al. (2004) ), HSP70-hom (Bogunia-Kubik & Lange (2005) ) and IL12B (Cargill et al. (2007) )) or inflammatory disease and GvHD (Novota et al. (2011) ) (C3 (Park et al. (2009) ), LOX1 ) and CD91 (Chalmers et al. (2010) )).
The majority of the cohort after the year 2000 had high-resolution tissue typing for HLA Class I A,B,C and Class II DP,DQ and DR.
Statistical analysis
The impact of selected non-HLA genetic factors on survival, non-relapse mortality (NRM) (Iacobelli (2013) ), relapse and GvHD was assessed using Kaplan-Meier, Cox regression and competing risks (Marubini & Valsecchi (1996) ) techniques.
For modelling overall survival, biallelic SNPs were considered under the additive, dominant and recessive modes of inheritance (Chien, et al. (2012) ). For a specific SNP, the mode showing the strongest association with survival was entered into the final model. All available genetic variables were used as candidates for Cox regression model building, these were entered into a stepwise variable selection modelling procedure alongside the EBMT risk score.
A significance level of 0.05 was used for variable entry and 0.1 for removal.
Predictive accuracy of the models was quantified using the concordance index (C-index) (Harrell et al. (1982) ) and prediction error (i.e. 0.632+ bootstrap estimator) (Gerds & Schumacher (2007) ). A larger value of the concordance index (C-index) means that lower risk score correlates with longer survival time (C-index=1 means perfect predictive discrimination; C-index=0.5 means no predictive discrimination). The method of prediction error curve generation utilises a bootstrapping procedure whereby a model is generated using training data and validated using a test data set. The procedure is repeated 1000 times and, for each repetition, a training set of size N is extracted from the full data set (also of size N) using sampling with replacement; the remaining data (not used in the training sample) act as a test set. For each iteration, differences are found between actual and predicted responses in the test set and essentially an average residual is found. When several models are compared, a lower prediction error curve signifies that the associated model has a better predictive performance R (v3.1.2), Minitab (v17), SAS (v9.4) and SPSS-23 were used for the computations.
Results
Clinical Characteristics
As transplant protocols have changed with time, we assessed clinical differences in patients treated up to and after the year 2000. The Chi-square test was employed for this task utilising exact P-values (Table 1) .
The majority of patients in this study underwent HSCT after the year 2000 (63%). Transplants post year 2000 involved more patients and donors over 40 years of age, more HLA-matched unrelated donors, more peripheral blood stem cell transplants, more T cell depleted transplants and more reduced intensity conditioning (RIC) protocols (Table 1) .
Analysis of Genetic Factors
Overall survival was initially studied. Kaplan-Meier survival curves and associated log rank tests were generated for each individual gene polymorphism. Variables showing a significant difference between survival curves (P-value < 0.05) are displayed in Table 2 and include MAL (rs8177374), the glucocorticoid receptor (GCR) haplotype (consisting of rs6198, rs33389 and rs33388), IL1RN (rs419598) and IL4 (rs2243250) in the patient together with the IL10 haplotype (consisting of rs1800896, rs1800871 and rs1800872) and MDR1 (rs1045642) in the donor.
Model Construction
The multivariate Cox regression model was generated with N=204 (a reduction from N=458 due to missing data). A missing value assessment was carried out to check that there was no difference between the group of cases omitted and the group of cases included for statistical analysis. The difference between survival functions for the two groups was non significant Single nucleotide polymorphisms (SNPs) in three genes were found to improve the goodness of fit of the model when viewed alongside the EBMT risk score. Presence of MAL (rs8177374) allele T in the patient (HR:1.54, 95% CI:1.04-2.30), absence of the GCR haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the patient (HR:0.67, 95% CI:0.46-0.98) and absence of heat shock protein 70-hom (HSP70-hom +2437) (rs2227956) allele C in the patient (HR:0.56, 95% CI:0.36-0.88) were associated with decreased survival time (Table 3) .
Univariate log rank tests for the individual predictors and the associated Kaplan-Meier plots are shown in Supplementary Figure 1 . Every predictor showed a log rank statistic with P-value <0.05 except patient HSP70-hom (+2437) (rs2227956) allele C (P-value = 0.245). This variable was therefore more weakly associated with overall survival when viewed on its own but an important predictor when viewed alongside other variables. Predictors having univariate statistics with P-value < 0.25 are deemed to be satisfactory candidate variables in multivariate modelling (Hosmer & Lemeshow (2000) ).
The resulting model enabled an integer score (clinical-genetic-score) to be assigned to each patient. The clinical-genetic-score was calculated via a summation process of the model's individual elements (Supplementary Section A). To make the scoring instrument easier to use in a clinical setting, individual elements were obtained by dividing the regression coefficients by the coefficient of the EBMT risk score and rounding to the nearest whole number (Table 3, Supplementary Section A). A higher risk score indicated a worse prognosis.
For the cases in the study set, the EBMT risk score ranged from 0 to 7 (low to high risk);
clinical-genetic-scores ranged from 1 to 13 (no patient had the minimum possible score of 0 or maximum possible score of 14). After observing resulting Kaplan-Meier curves for the individual clinical-genetic-scores and grouping categories which naturally fell together (results not shown), 'low risk' could be categorized as having scores 1-6, 'intermediate risk': scores 7-8 and 'high risk': scores 9-13. A Kaplan-Meier plot displaying good separation of the three resulting survival curves is shown in Figure 1A . Furthermore the hazard ratio (HR) in a Cox regression significantly increased when compared to the low risk group (intermediate risk HR:
1.70, 95% CI: 1.10-2.63; high risk HR: 3.25, 95% CI: 2.06-5.12). A Kaplan-Meier plot for the EBMT risk score is also provided for comparison ( Figure 1B) , it was clear that the risk categories of the clinical-genetic-score had better separated (and consistently ordered) survival curves when compared to those of the EBMT risk score for this data set.
Next, prediction error curves (utilising a bootstrapping procedure and incorporating validation sets) were used to compare a model containing the single EBMT risk score, a model containing EBMT risk score and the three polymorphisms and a model containing no factors (i.e. the Kaplan-Meier curve). A comparison of each model is given in Figure 2 . The lower prediction error curve for the model containing EBMT risk score and the three polymorphisms signified that it had a better predictive value. Furthermore, the C-index showed that the risk score groups generated from a model containing SNPs correlated better with actual survival time when compared with a model containing the EBMT risk score alone (0.62 versus 0.59, P-value=0.012), the hazard ratio was also higher (HR: 1.80, 95% CI:1.43-2.26 versus HR: 1.21, 95% CI: 1.10-1.40).
Association with Other Outcomes
After further analysis of the SNPs for association with NRM and relapse, Gray's test (Gray (1988) ) indicated that presence of MAL (rs8177374) allele T in the patient (P-value = 0.031) and absence of the GCR haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the patient (P-value = 0.026) were associated with an increased incidence of relapse (Supplementary Tables 4A-B) . The genetic variables were also studied for their association with acute GvHD I-IV, II-IV, III-IV and chronic GvHD. It was found that the presence of the GCR haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the patient was weakly associated with chronic GvHD (P-value = 0.075).
Discussion
One of the problems of SNP association studies in HSCT is the heterogeneity of the cohort in terms of diagnosis, type of conditioning, GvHD prophylaxis and donor type. For this reason, this study focused on one disease group, acute leukaemia. For this disease, a risk scoring instrument was established which included three polymorphisms together with the EBMT risk score. Presence of MAL (rs8177374) allele T in the patient, absence of the GCR haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the patient and absence of HSP70-hom +2437 (rs2227956) allele C in the patient were associated with decreased survival. The subsequent score assigned to each patient was termed the clinical-genetic-score and could be easily derived by means of summation of risk score points assigned to each of the model's elements. Moreover, in practice, polymorphisms in the patient could be typed at the same time as donor tissue is typed (pre-transplant) and this makes the clinical-geneticscore no less accessible than the EBMT risk score. Patients could be assigned to low, intermediate and high risk score categories based on their clinical-genetic-score and identification of patients in the high risk group would ensure that they had a reduced time to transplant from diagnosis, younger donors, fully matched HLA donors (Kollman et al. (2001) ) (all associated with improved survival) and increased monitoring for GvHD/infection.
As expected, there was a strong correlation between the EBMT risk score and clinicalgenetic-score (Spearman's r = 0.676; P-value < 0.0005, N=204) but validation of the models via a bootstrapping procedure indicated that the clinical-genetic-score had improved predictive value when compared to the EBMT risk score alone and, additionally, prognostic risk categories derived from the clinical-genetic-score showed more distinct separation of Figure 2B) . Holtick et al. (2008) found that patients homozygous for the T allele of MAL (rs8177374) had an increased risk of relapse whilst, in the donors, the presence of the T allele resulted in less cGvHD. Interestingly, Rocha et al. (2007) found, that presence of the T allele of rs8177374 in donors resulted in less transplant related mortality. The T allele is regarded in the literature as the inflammatory allele and individuals heterozygous for this SNP have increased protection from infection. Patients transplanted from donors with the T allele have also been shown to have a lower incidence of fungal infections, lower incidence of acute GvHD and improved overall survival (Rocha, et al. (2007) ). The MAL protein was originally identified in intermediate and late stages of T-lymphocyte differentiation (Alonso & Weissman (1987)) and is an internal component of glycolipid-enriched membrane domains in T-lymphocytes (Millán et al. (1997) ). It may be important in T cell signalling and thus associated with reduced or improved survival depending on the role of the T cells e.g. associated GvL or GvHD effects. It is also important in the innate immune response and it is involved in Tolllike receptor (TLR) 2 and 4 signalling (Yamamoto et al. (2002) ).
The GCR binds glucocorticoids in the cytoplasm and transports them to the nucleus where they influence the expression of many inflammatory genes such as interleukin (IL) IL1, IL2, IL3, IL6, IL8 and TNF causing their down regulation (Chikanza et al. (2003) ). In addition, glucocorticoids can also induce the transcription of anti-inflammatory genes including IL4, IL10 and IL13 (Chikanza, et al. (2003) ). The ACT haplotype is made up of two of the putative GC resistant, inflammatory alleles, the C allele of rs33389 and the T allele of rs33388.
There is a well-documented association between the occurrence of cGvHD and reduced relapse risk in HSCT (Signori et al. (2012) ) and this is borne out in our results with the ACT haplotype of the GCR in the patient showing a trend to association with cGvHD and the absence of this haplotype also being associated with decreased survival and with increased relapse. This putative inflammatory haplotype might be aiding the graft versus leukaemia (GvL) effect as well as cGvHD and therefore the absence of this haplotype would result in a more immunosuppressed phenotype in the patient leading to decreased survival.
There was a trend towards an association between recipient HSP70-hom +2437 (rs2227956) genotype TT and incidence of acute GvHD (P-value = 0.127). Past studies have shown a relationship between another HSP70-hom SNP, rs2075800, in recipients and GvHD with genotype AA presenting more frequently with grade II to IV toxic lesions and acute GvHD (Bogunia-Kubik & Lange (2005) ). Another study has shown an association between HSP70-hom +2437 (rs2227956) and treatment related mortality with the TT genotype in patients displaying a protective effect but the study was limited to a small cohort (N=147) (Kim et al. (2010) ). HSP70-hom belongs to a highly conserved family of proteins, intracellular HSPs function as molecular chaperones facilitating the folding or transport of other proteins following physical or chemical stress (Matouschek (2003) ). Extracellular HSPs are important in the cellular immune response acting as carrier molecules for antigen peptides (Srivastava et al. (1994) ) and they may by themselves activate the innate immune response (Asea et al. (2000) ).
This AL data set forms part of a previously analysed larger cohort which included other disease types: CML, lymphoma, plasma cell neoplasia, myelodysplasia syndrome and chronic myelomonocytic leukaemia (Balavarca, et al. (2015) ). Here, a prognostic index for overall survival was also derived using the EBMT risk score and additional genetic polymorphisms (haplo-genotype ACC/ACC of IL10 in donors, MAL rs8177374 in patients, ESR1 rs9340799 in patients and IL6 rs1800795 in donors). MAL rs8177374 in patients is common to both models with allele T being associated with reduced overall survival.
Additionally, univariate similarities between the two cohorts were also present with a protective effect being observed for IL10 haplo-genotype ACC/ACC, IL4 rs2243250 (allele T) and GCR rs33388 (allele T) and a reduced survival effect for MAL rs8177374 (allele T) and IL10 rs1800896 (allele G). Although, the purpose of the current (acute leukaemia) study is not to directly contrast and compare the two statistical models, we did find clear similarities when they were viewed alongside the established EBMT risk score (better differentiation of risk groups, increased predictive value and clear identification of improved survival probability for patients transplanted after 2000) . Both studies hence illustrate the importance of including genetic as well as clinical information in a pre-transplant risk scoring procedure and reflect the influence of polymorphisms which suppress the immune response giving rise to reduced survival (possibly due to reduced GvL effects) (Dickinson et al. (2010) , Pearce et al. (2012 ), Balavarca, et al. (2015 ).
In conclusion, the established EBMT risk score, although easily accessible pre-transplant, is recognised as not being optimal. Utilising clinical and genetic factors could be one way to improve pre-transplant clinical risk assessment. In a recent review, the relationship of the EBMT risk score with outcome was indeed shown to depend on other factors such as CMV status and Karnofsky score (Gratwohl (2012) ). In future, further SNPs could be identified via meta-analysis and these could be viewed in conjunction with specific protein levels and/or mRNA and microRNA levels of putative biomarkers. In addition, large cohort analysis could enable combined patient and donor SNPs to be used as supplementary predictors in HSCT. 
